XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Cash flows from operating activities:              
Net loss $ (45,496,672) $ (19,694,697) $ (25,165,478) $ (30,469,871) $ (88,710,781) $ (87,872,447)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,077,716 1,335,326  
Amortization of operating lease right-of-use assets         1,157,060 1,018,887  
Change in fair value of common stock warrant liabilities 22,515,730   0   20,680,868 0  
Non-cash stock-based compensation         2,991,227 5,279,344  
Non-cash interest on senior convertible notes         0 (355,654)  
Amortization of discounts on investments         50,867 (1,510,276)  
Loss on sales of short-term investments         890,888 1,278,959  
Loss on disposal of fixed assets         0 21,930  
(Gain) loss on equity investment in affiliated entity 589,618   (324,251)   (881,886) 136,061  
Net unrealized gain on available-for-sale equity securities (205,259)   (1,330,811)   (1,104,782) (1,810,868)  
Changes in operating assets and liabilities:              
Accounts receivable from affiliated entity         220,466 542,489  
Prepaid expenses and other current assets         (881,069) 796,981  
Other assets         (32,822) 38,900  
Accounts payable and accrued expenses, including due to affiliated entity         (1,847,935) (4,340,806)  
Accrued clinical trial expenses         (1,065,890) 2,131,186  
Operating lease right-of-use assets and liabilities, net         (1,844,960) (993,249)  
Grant funding liability, including from affiliated entity         42,152 (109,407)  
Net cash used in operating activities         (69,258,881) (84,412,644)  
Cash flows from investing activities:              
Purchases of investments         (4,946,073) (54,138,027)  
Proceeds from sale or maturity of investments         19,201,873 124,052,574  
Purchases of capital assets         (158,254) (487,832)  
Net cash provided by investing activities         14,097,546 69,426,715  
Cash flows from financing activities:              
Repayment of convertible senior notes         0 (16,415,000)  
Proceeds from issuance of common stock, net of issuance costs         8,287,277 22,951,867  
Proceeds from exercise of warrants and pre-funded warrants         752,134 0  
Proceeds from stock option exercises         0 67,675  
Taxes paid related to net share settlement of equity awards         (110,783) (420,795)  
Net cash provided by financing activities         25,915,458 22,330,144  
Effect of exchange rate changes on cash and cash equivalents         0 32,403  
(Decrease) Increase in cash and cash equivalents         (29,245,877) 7,376,618  
Cash and cash equivalents, beginning of period   $ 65,813,297   $ 14,310,862 65,813,297 14,310,862 $ 14,310,862
Cash and cash equivalents, end of period $ 36,567,420   $ 21,687,480   36,567,420 21,687,480 $ 65,813,297
Supplemental disclosures:              
Interest paid         0 533,487  
Pre-Funded Warrants              
Cash flows from financing activities:              
Proceeds from issuance of warrants, net of issuance costs         0 16,146,397  
Warrant              
Cash flows from financing activities:              
Proceeds from issuance of warrants, net of issuance costs         $ 16,986,830 $ 0